$4.39
3.09% day before yesterday
Nasdaq, Nov 01, 07:04 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Target price 2024 - Analyst rating & recommendation

Sonnet BioTherapeutics Holdings Inc Classifications & Recommendation:

Buy
100%

Sonnet BioTherapeutics Holdings Inc Price Target

Target Price $148.00
Price $4.32
Potential
Number of Estimates 2
2 Analysts have issued a price target Sonnet BioTherapeutics Holdings Inc 2025 . The average Sonnet BioTherapeutics Holdings Inc target price is $148.00. This is higher than the current stock price. The highest price target is
$240.00 5,455.56%
register free of charge
, the lowest is
$56.00 1,196.30%
register free of charge
.
A rating was issued by 2 analysts: 2 Analysts recommend Sonnet BioTherapeutics Holdings Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sonnet BioTherapeutics Holdings Inc stock has an average upside potential 2025 of . Most analysts recommend the Sonnet BioTherapeutics Holdings Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '23 2024
Estimates
Revenue Million $ 0.15 0.05
57.14% 66.67%
Net Margin -62,885.33% -34,944.00%
125.17% 44.43%

2 Analysts have issued a sales forecast Sonnet BioTherapeutics Holdings Inc 2024 . The average Sonnet BioTherapeutics Holdings Inc sales estimate is

$50.0k
Unlock
. This is
16.67% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$100k 66.67%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $150k 57.14%
2024
$50.0k 66.67%
Unlock
2025
$0.0 100.00%
Unlock

The average Sonnet BioTherapeutics Holdings Inc net profit estimate is

$-17.5m
Unlock
. This is
11.06% lower
Unlock
than the net profit for the last 12 months(TTM).

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-94.3m 3.50%
2024
$-17.5m 81.48%
Unlock
2025
$-2.0b 11,451.35%
Unlock

Net Margin

2023 -62,885.33% 125.17%
2024
-34,944.00% 44.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Sep '23 2024
Estimates
Earnings Per Share $ -145.12 -26.88
3.50% 81.48%
P/E negative
EV/Sales negative

The average Sonnet BioTherapeutics Holdings Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-26.88
Unlock
. This is
11.07% lower
Unlock
than earnings per share in the financial year 2023.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-145.12 3.50%
2024
$-26.88 81.48%
Unlock
2025
$-3,104.64 11,450.00%
Unlock

P/E ratio

Current -0.18 800.00%
2024
-0.16 11.11%
Unlock
2025
0.00 100.00%
Unlock

Based on analysts' sales estimates for 2024, the Sonnet BioTherapeutics Holdings Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-9.00
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
59.00
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -7.50 73.39%
2024
-9.00 20.00%
Unlock

P/S ratio

Current 49.17 315.84%
2024
59.00 20.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today